par Marechal, Raphaël 
;Bachet, Jean-Baptiste;Mackey, John R;Dalban, Cécile;Demetter, Pieter ;Graham, Kathryn;Couvelard, Anne;Svrcek, Magali;Bardier-Dupas, Armelle;Hammel, Pascal;Sauvanet, Alain;Louvet, Christophe;Paye, François;Rougier, Philippe;Penna, Christophe;André, Thierry;Dumontet, Charles;Cass, Carol E;Jordheim, Lars Petter;Louvet, Christophe;Closset, Jean ;Salmon, Isabelle ;Devière, Jacques ;Emile, Jean-François;Van Laethem, Jean-Luc
Référence Gastroenterology, 143, 3, page (664-674), e1-6
Publication Publié, 2012-09
;Bachet, Jean-Baptiste;Mackey, John R;Dalban, Cécile;Demetter, Pieter ;Graham, Kathryn;Couvelard, Anne;Svrcek, Magali;Bardier-Dupas, Armelle;Hammel, Pascal;Sauvanet, Alain;Louvet, Christophe;Paye, François;Rougier, Philippe;Penna, Christophe;André, Thierry;Dumontet, Charles;Cass, Carol E;Jordheim, Lars Petter;Louvet, Christophe;Closset, Jean ;Salmon, Isabelle ;Devière, Jacques ;Emile, Jean-François;Van Laethem, Jean-Luc Référence Gastroenterology, 143, 3, page (664-674), e1-6
Publication Publié, 2012-09
Article révisé par les pairs
| Résumé : | Patients who undergo surgery for pancreatic ductal adenocarcinoma (PDAC) frequently receive adjuvant gemcitabine chemotherapy. Key determinants of gemcitabine cytotoxicity include the activities of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), and ribonucleotide reductase subunit 1 (RRM1). We investigated whether tumor levels of these proteins were associated with efficacy of gemcitabine therapy following surgery. |
